Joseph Selsavage - 01 Sep 2022 Form 3 Insider Report for 23andMe Holding Co. (ME)

Role
Interim CFO
Signature
/s/ Joseph Selsavage, by Kathy Hibbs, attorney-in-fact
Issuer symbol
ME
Transactions as of
01 Sep 2022
Transactions value $
$0
Form type
3
Date filed
02 Sep 2022, 16:00
Next filing
22 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ME Class A Common Stock 158K 01 Sep 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ME Stock Option (Right to Buy) 01 Sep 2022 Class A Common Stock 521K $0.96 Direct F1
holding ME Stock Option (Right to Buy) 01 Sep 2022 Class A Common Stock 80.5K $3.56 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Received in the November 2021 merger in which the issuer acquired Lemonaid Health, Inc. ("Lemonaid Health") in exchange for an option to purchase 384,340 shares of common stock of Lemonaid Health. The stock options vest over a four-year period, with an initial 25% vesting on November 1, 2021, and the remainder vesting on a monthly basis thereafter.
F2 The stock options vest equally in 1/48 monthly installments beginning on May 1, 2022.